Overview |
bs-5435R |
TAK1(Ser192) Polyclonal Antibody |
WB, ELISA, FCM, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC) |
Human, Rat |
Mouse, Cow, Pig, Horse, Chicken, Rabbit |
Specifications |
Unconjugated |
Rabbit |
KLH conjugated synthetic phosphopeptide derived from human TAK1 around the phosphorylation site of Ser192 |
Ser192 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
Target |
7182 |
Cytoplasm, Cell membrane |
MAP3K7phospho S192; M3K7_HUMAN; MAP3K 7; Map3k7; MEKK7; Mitogen activated protein kinase kinase kinase 7; Mitogen-activated protein kinase kinase kinase 7; Mitogen-activated protein kinase kinase kinase 7; TAK1; TGF beta activated kinase 1; TGF-beta-activated kinase 1; TGF1a; Transforming growth factor beta activated kinase 1; Transforming growth factor-beta-activated kinase 1. |
TAK1 (or MAP3K7) was shown to participate in regulation of transcription by transforming growth factor beta (TGF beta). TAK1 is stimulated in response to TGF beta and bone morphogenetic protein. These results suggest that TAK1 functions as a mediator in the signaling pathway of TGF beta superfamily members. TAB1 and TAB2 are TAK1 binding proteins that may function as activators of the TAK1 (TGF b activated kinase 1) MAPKKK in TGF b signal transduction. TAB1 induced TAK1 activation promoted the dissociation of active forms of IKKa and IKK b from active TAK1, whereas the IKK mutants remained to interact with active TAK1. TNF a activated endogenous TAK1, and the kinase negative TAK1 acted as a dominant negative inhibitor against TNF a induced NFkB activation. TAK1 was suggested to act as a regulatory kinase of IKKs. |
Application Dilution |
WB |
1:300-5000 |
ELISA |
1:500-1000 |
FCM |
1:20-100 |
IHC-P |
1:200-400 |
IHC-F |
1:100-500 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |